QOP
HUMA icon

Quinn Opportunity Partners’s Humacyte HUMA Stock Holding History

Quinn Opportunity Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,000
Closed -$113K – 387
2025
Q3 		$113K Hold
65,000
– – 0.01% 300
2025
Q2 		$136K Hold
65,000
– – 0.01% 314
2025
Q1 		$111K Hold
65,000
– – 0.01% 362
2024
Q4 		$328K Buy
+65,000
New +$322K 0.02% 296

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quinn Opportunity Partners's HUMA Position: Q4 2025 in Review

Quinn Opportunity Partners sold out of Humacyte (HUMA) in Q4 2025, closing a stake of 65,000 shares — an estimated $113K sold.

Quinn Opportunity Partners first reported a position in HUMA in Q4 2024 and held it in 4 quarters. The position peaked at $328K in Q4 2024. 147 funds tracked by Wall St. Rank hold HUMA as of Q4 2025.

  • Quinn Opportunity Partners reported no remaining Humacyte position as of Q4 2025 after selling out during the quarter.
  • Quinn Opportunity Partners sold 65,000 Humacyte shares in Q4 2025, an estimated $113K.
  • Quinn Opportunity Partners first reported a position in Humacyte in Q4 2024 and held it in 4 quarters.
  • Quinn Opportunity Partners's Humacyte position peaked at $328K in Q4 2024.
  • 147 funds tracked by Wall St. Rank held Humacyte as of Q4 2025.

Based on Quinn Opportunity Partners's 13F filing for Q4 2025, filed 13 Feb 2026.